Clinolipid + Intralipid
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Essential Fatty Acid Deficiency (EFAD)
Conditions
Essential Fatty Acid Deficiency (EFAD)
Trial Timeline
Jan 22, 2021 → Nov 16, 2022
NCT ID
NCT04555044About Clinolipid + Intralipid
Clinolipid + Intralipid is a approved stage product being developed by Baxter for Essential Fatty Acid Deficiency (EFAD). The current trial status is completed. This product is registered under clinical trial identifier NCT04555044. Target conditions include Essential Fatty Acid Deficiency (EFAD).
What happened to similar drugs?
14 of 20 similar drugs in Essential Fatty Acid Deficiency (EFAD) were approved
Approved (14) Terminated (2) Active (6)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04555044 | Approved | Completed |
| NCT02476994 | Approved | Terminated |
Competing Products
20 competing products in Essential Fatty Acid Deficiency (EFAD)